Product Code: MD 6602
The market for rapid microbiology testing is projected to grow from USD 5.69 billion in 2026 to USD 9.00 billion by 2031, reflecting a CAGR of 9.6%. Market growth is supported by rising pharmaceutical and biopharmaceutical production, stringent sterility and contamination control requirements, and expanding use of molecular diagnostics and automated microbiology systems.
| Scope of the Report |
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Product, Method, Application, End User, Region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
Additionally, advancements in Polymerase Chain Reaction (PCR), mass spectrometry, and rapid microbial identification technologies are improving laboratory efficiency and supporting broader adoption globally.
"By product, reagents & Kits segment to showcase highest CAGR during forecast period"
The growth of the reagents & kits segment is primarily driven by the recurring demand for culture media, assay kits, primers, probes, stains, buffers, and antimicrobial susceptibility testing reagents used in rapid microbiology workflows. Rising incidences of infectious diseases and increasing emphasis on sterility assurance and contamination control are accelerating testing volumes across hospitals, pharmaceutical & biotechnology companies, and food testing laboratories. Additionally, expanding adoption of molecular microbiology techniques, automated testing platforms, and rapid PCR-based assays is expected to further drive demand for reagents & kits throughout the forecast period.
"By method, growth-based segment to hold the largest share of rapid microbiology testing market in 2026"
A growth-based rapid microbiology testing method is likely to dominate the market in 2026 due to its extensive use in pharmaceutical sterility testing, environmental monitoring, food safety testing, and clinical microbiology workflows. Growth-based rapid microbiology methods are widely adopted because they provide reliable detection of viable microorganisms while supporting regulatory compliance and quality assurance requirements. The increasing adoption of automated microbial detection systems, rising demand for faster contamination identification, and growing pharmaceutical and biopharmaceutical manufacturing activities are further driving segment growth. Additionally, the need for rapid product release and improved laboratory efficiency continues to support demand for growth-based testing methods.
"Asia Pacific to register fastest growth rate in rapid microbiology testing market during forecast period"
The region is witnessing significant growth due to expanding healthcare infrastructure, increasing healthcare expenditure, and rapid modernization of hospitals, diagnostic laboratories, and pharmaceutical manufacturing facilities. Rising prevalence of infectious diseases and growing awareness regarding contamination control and patient safety are increasing the demand for rapid microbial diagnostics across the region. Additionally, increasing investments in biotechnology research, biopharmaceutical production, and laboratory automation are further supporting market expansion. The growing adoption of molecular diagnostics, rapid PCR systems, and automated microbial identification technologies is also contributing to market growth. Major countries driving regional expansion include China, India, Japan, and South Korea.
Breakdown of primary participants in the rapid microbiology testing market is as follows:
- By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
- By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
- By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)
The key players in the rapid microbiology testing market are bioMerieux (France), Waters Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), Bruker Corporation (US), QuidelOrtho Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Charles River Laboratories International, Inc. (US), Neogen Corporation (US), Bio-Rad Laboratories, Inc. (US), Shimadzu Corporation (Japan), and Rapid Micro Biosystems, Inc. (US).
Research Coverage:
This research report categorizes the rapid microbiology testing market by product (consumables, instruments, reagents & kits), method (growth-based, cellular component-based, nucleic acid-based, viability-based, and other methods) application (industrial testing, clinical disease diagnosis, and research applications), end user (hospitals, clinical laboratories, & ASCs; pharmaceutical & biotechnology companies; food & beverage companies; environmental & water testing laboratories; and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the rapid microbiology testing market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, and key strategies, such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the rapid microbiology testing market. This report covers the competitive analysis of upcoming startups in the rapid microbiology testing ecosystem.
Reasons to Buy This Report:
The report will help leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall rapid microbiology testing market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (increasing burden of healthcare-associated infections (HAIs), antimicrobial resistance (AMR), and infectious diseases; technological advancements in automated microbiology and MALDI-TOF platforms; growing food safety concerns and rising incidence of foodborne illnesses; increasing R&D activities in microbiology and infectious disease), restraints (high capital investments and low cost-benefit ratio, unfavorable regulatory and reimbursement scenario, shortage of skilled personnel), opportunities (growing demand for rapid microbiology testing in emerging economies, expansion of rapid microbial testing applications), and challenges (operational barriers, high investment for automated microbial identification systems)
- Product development/innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the rapid microbiology testing market.
- Market development: Comprehensive information about lucrative markets; the report analyzes the rapid microbiology testing market across varied regions.
- Market diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the rapid microbiology testing market.
- Competitive assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like bioMerieux (France), Waters Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), and Thermo Fisher Scientific, Inc. (US).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING MARKET
- 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 RAPID MICROBIOLOGY TESTING MARKET OVERVIEW
- 3.2 RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT, 2026 VS. 2031
- 3.3 RAPID MICROBIOLOGY TESTING MARKET, BY METHOD, 2026 VS. 2031
- 3.4 RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION, 2026 VS. 2031
- 3.5 RAPID MICROBIOLOGY TESTING MARKET, BY END USER, 2026 VS. 2031
- 3.6 RAPID MICROBIOLOGY TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Increasing burden of healthcare-associated infections (HAIs), antimicrobial resistance (AMR), and infectious diseases
- 4.2.1.2 Technological advancements in automated microbiology and MALDI-TOF platforms
- 4.2.1.3 Growing food safety concerns and rising incidence of foodborne illnesses
- 4.2.1.4 Increasing R&D in microbiology and infectious diseases
- 4.2.2 RESTRAINTS
- 4.2.2.1 High capital investments and low cost-benefit ratio
- 4.2.2.2 Unfavorable regulatory and reimbursement scenario
- 4.2.2.3 Shortage of skilled personnel
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Growing demand for rapid microbiology testing in emerging economies
- 4.2.3.2 Expansion of rapid microbial testing applications
- 4.2.4 CHALLENGES
- 4.2.4.1 Operational barriers
- 4.2.4.2 High investment for automated microbial identification systems
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.3.1 UNMET NEEDS IN RAPID MICROBIOLOGY TESTING MARKET
- 4.3.2 WHITE SPACE OPPORTUNITIES
- 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
- 4.4.1 INTERCONNECTED MARKETS
- 4.4.2 CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
- 4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 BARGAINING POWER OF SUPPLIERS
- 5.1.2 BARGAINING POWER OF BUYERS
- 5.1.3 THREAT OF NEW ENTRANTS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC INDICATORS
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS AND FORECAST
- 5.3 SUPPLY CHAIN ANALYSIS
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.5.1 RAPID MICROBIOLOGY TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
- 5.6 PRICING ANALYSIS
- 5.6.1 AVERAGE SELLING PRICE OF RAPID MICROBIOLOGY TESTING PRODUCTS, BY KEY PLAYER, 2024-2026
- 5.6.2 AVERAGE SELLING PRICE OF RAPID MICROBIOLOGY TESTING PRODUCTS, BY REGION, 2024-2026
- 5.7 TRADE ANALYSIS
- 5.7.1 IMPORT SCENARIO (HS CODE 3822)
- 5.7.2 EXPORT SCENARIO (HS CODE 3822)
- 5.8 KEY CONFERENCES & EVENTS, 2026-2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.10 INVESTMENT & FUNDING SCENARIO
- 5.11 CASE STUDY ANALYSIS
- 5.11.1 YOUNGS SEAFOOD ACCELERATED FOOD TESTING WITH VIDAS
- 5.11.2 RAPID MICROBIOLOGICAL METHOD CASE STUDY FOR ADVANCED THERAPY MEDICINAL PRODUCTS
- 5.11.3 RAPID DETECTION METHOD OF BACTERIAL PATHOGENS IN SURFACE WATERS AND NEW RISK INDICATOR FOR WATER PATHOGENIC POLLUTION
- 5.12 IMPACT OF US TARIFFS-RAPID MICROBIOLOGY TESTING MARKET
- 5.12.1 INTRODUCTION
- 5.12.2 KEY TARIFF RATES
- 5.12.3 PRICE IMPACT ANALYSIS
- 5.12.4 IMPACT ON COUNTRIES/REGIONS
- 5.12.4.1 North America
- 5.12.4.2 Europe
- 5.12.4.3 Asia Pacific
- 5.12.5 IMPACT ON END-USE INDUSTRIES
- 5.12.5.1 Hospitals, Clinical Laboratories, and ASCs
- 5.12.5.2 Pharmaceutical & Biotechnology Companies
- 5.12.5.3 Food & Beverage Companies
- 5.12.5.4 Environmental & Water Testing Laboratories
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 AUTOMATED MULTIPLEX PCR SYSTEMS
- 6.1.2 BIOSENSORS
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 OPTICAL IMMUNOSENSORS
- 6.2.2 ELECTROCHEMICAL IMMUNOSENSORS
- 6.3 ADJACENT TECHNOLOGIES
- 6.4 TECHNOLOGY/PRODUCT ROADMAP
- 6.5 PATENT ANALYSIS
- 6.5.1 LIST OF MAJOR PATENTS
- 6.6 FUTURE APPLICATIONS
- 6.7 IMPACT OF AI/GENERATIVE AI ON RAPID MICROBIOLOGY TESTING MARKET
- 6.7.1 INTRODUCTION
- 6.7.2 TOP USE CASES AND MARKET POTENTIAL
- 6.7.3 KEY COMPANIES IMPLEMENTING AI
- 6.7.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 INDUSTRY STANDARDS
- 7.2 SUSTAINABILITY INITIATIVES
- 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN RAPID MICROBIOLOGY TESTING
- 7.2.1.1 Eco-friendly Initiatives
- 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 BUYING CRITERIA
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
- 8.5 MARKET PROFITABILITY
- 8.5.1 REVENUE POTENTIAL
- 8.5.2 COST DYNAMICS
- 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT
- 9.1 INTRODUCTION
- 9.2 INSTRUMENTS
- 9.2.1 AUTOMATED MICROBIAL IDENTIFICATION & ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS
- 9.2.1.1 Ease of use compared to conventional identification processes to support market growth
- 9.2.2 MASS SPECTROMETERS
- 9.2.2.1 Rapid results associated with mass spectrometry methods to boost adoption
- 9.2.3 BIOLUMINESCENCE & FLUORESCENCE-BASED DETECTION SYSTEMS
- 9.2.3.1 Unwanted detection of non-microbial ATP to limit market adoption
- 9.2.4 PCR SYSTEMS
- 9.2.4.1 Growing use of standard, real-time, and qPCR for rapid microbial testing to support growth
- 9.2.5 CYTOMETERS
- 9.2.5.1 Ability to detect viable organisms to favor market growth
- 9.2.6 ACTIVE AIR SAMPLERS
- 9.2.6.1 Convenience and ease of use to drive demand for active air samplers
- 9.2.7 OTHER INSTRUMENTS
- 9.3 REAGENTS & KITS
- 9.3.1 STERILITY TESTING REAGENTS & KITS
- 9.3.1.1 Increasing adoption of BET assays to propel market growth
- 9.3.2 OTHER REAGENTS & KITS
- 9.4 CONSUMABLES
- 9.4.1 DEVELOPMENT OF AUTOMATED ZONE READERS AND DISPENSERS TO DRIVE MARKET GROWTH
10 RAPID MICROBIOLOGY TESTING MARKET: VOLUME ANALYSIS
- 10.1 INTRODUCTION
- 10.2 GLOBAL: VOLUME OF MALDI-TOF MS MICROBIAL IDENTIFICATION SYSTEM INSTALLED BASE
11 RAPID MICROBIOLOGY TESTING MARKET, BY METHOD
- 11.1 INTRODUCTION
- 11.2 GROWTH-BASED RAPID MICROBIOLOGY TESTING
- 11.2.1 RISING DEMAND FOR GROWTH-BASED TESTING TO DRIVE MARKET
- 11.3 CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING
- 11.3.1 HIGH SENSITIVITY, ACCURACY, AND SPECIFICITY OF CELLULAR COMPONENT-BASED METHODS TO BOOST MARKET
- 11.4 NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING
- 11.4.1 HIGH ACCURACY ASSOCIATED WITH NUCLEIC ACID-BASED METHODS TO FAVOR MARKET GROWTH
- 11.5 VIABILITY-BASED RAPID MICROBIOLOGY TESTING
- 11.5.1 NEAR REAL-TIME DETECTION AND IMPROVED ACCURACY TO DRIVE DEMAND
- 11.6 OTHER METHODS
12 RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION
- 12.1 INTRODUCTION
- 12.2 INDUSTRIAL TESTING
- 12.2.1 FOOD & BEVERAGE TESTING
- 12.2.1.1 Stringent quality control and quality assurance processes to drive market growth
- 12.2.2 PHARMACEUTICAL & BIOLOGICAL DRUG TESTING
- 12.2.2.1 Improved regulatory scenario for drug development to support market growth
- 12.2.3 ENVIRONMENTAL TESTING
- 12.2.3.1 Growing focus on environmental monitoring to boost segmental growth
- 12.2.4 COSMETIC & PERSONAL CARE PRODUCTS TESTING
- 12.2.4.1 Growing use of rapid microbiology testing to determine the presence of microbes favors market growth
- 12.2.5 OTHER INDUSTRIAL TESTING APPLICATIONS
- 12.3 CLINICAL DISEASE DIAGNOSIS
- 12.3.1 HIGH BURDEN OF INFECTIOUS DISEASES AND HEALTHCARE-ASSOCIATED INFECTIONS TO PROPEL MARKET GROWTH
- 12.4 RESEARCH
- 12.4.1 INCREASING NUMBER OF EPIDEMIOLOGY-BASED RESEARCH STUDIES TO DRIVE MARKET GROWTH
13 RAPID MICROBIOLOGY TESTING MARKET, BY END USER
- 13.1 INTRODUCTION
- 13.2 HOSPITALS, CLINICAL LABORATORIES, AND ASCS
- 13.2.1 INCREASING PATIENT VOLUME AND RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
- 13.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 13.3.1 STRINGENT GMP AND CONTAMINATION CONTROL REQUIREMENTS TO DRIVE TESTING DEMAND
- 13.4 FOOD & BEVERAGE COMPANIES
- 13.4.1 STRINGENT FOOD SAFETY REGULATIONS AND QUALITY CONTROL TO SUPPORT MARKET GROWTH
- 13.5 ENVIRONMENTAL & WATER TESTING LABORATORIES
- 13.5.1 GROWING FOCUS ON WATER SAFETY AND ENVIRONMENTAL MONITORING TO DRIVE DEMAND
- 13.6 OTHER END USERS
14 RAPID MICROBIOLOGY TESTING MARKET, BY REGION
- 14.1 INTRODUCTION
- 14.2 NORTH AMERICA
- 14.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
- 14.2.2 US
- 14.2.2.1 Increasing prevalence of infectious diseases to drive market
- 14.2.3 CANADA
- 14.2.3.1 Supportive government initiatives and increased research funding to boost market
- 14.3 EUROPE
- 14.3.1 EUROPE: MACROECONOMIC OUTLOOK
- 14.3.2 GERMANY
- 14.3.2.1 Favorable government policies to propel market
- 14.3.3 FRANCE
- 14.3.3.1 Favorable healthcare reforms and investments in diagnostic infrastructure to drive market
- 14.3.4 UK
- 14.3.4.1 Emphasis on food contamination monitoring and hygiene controls to drive market
- 14.3.5 ITALY
- 14.3.5.1 Improved healthcare services and better disease surveillance to support market growth
- 14.3.6 SPAIN
- 14.3.6.1 Water monitoring mandate to boost market growth
- 14.3.7 RUSSIA
- 14.3.7.1 Strengthening water quality surveillance and outbreak response drives adoption in Russia
- 14.3.8 REST OF EUROPE
- 14.4 ASIA PACIFIC
- 14.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
- 14.4.2 CHINA
- 14.4.2.1 Increasing government focus on disease prevention to drive market
- 14.4.3 JAPAN
- 14.4.3.1 Stringent safety laws and foodborne outbreaks to fuel uptake
- 14.4.4 INDIA
- 14.4.4.1 High target patient population to boost demand
- 14.4.5 SOUTH KOREA
- 14.4.5.1 Favorable government initiatives for medical tourism to support market growth
- 14.4.6 AUSTRALIA
- 14.4.6.1 Favorable healthcare automation techniques to support market growth
- 14.4.7 REST OF ASIA PACIFIC
- 14.5 LATIN AMERICA
- 14.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
- 14.5.2 BRAZIL
- 14.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market
- 14.5.3 MEXICO
- 14.5.3.1 Increasing prevalence of HIV to drive market
- 14.5.4 REST OF LATIN AMERICA
- 14.6 MIDDLE EAST & AFRICA
- 14.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
- 14.6.2 SAUDI ARABIA
- 14.6.2.1 Increasing focus on healthcare automation to drive market
- 14.6.3 UNITED ARAB EMIRATES (UAE)
- 14.6.3.1 Improvements in healthcare infrastructure to support market growth
- 14.6.4 REST OF MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
- 15.1 INTRODUCTION
- 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN RAPID MICROBIOLOGY TESTING MARKET
- 15.3 REVENUE ANALYSIS, 2023-2025
- 15.4 MARKET SHARE ANALYSIS, 2025
- 15.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
- 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 15.5.1 STARS
- 15.5.2 EMERGING LEADERS
- 15.5.3 PERVASIVE PLAYERS
- 15.5.4 PARTICIPANTS
- 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 15.5.5.1 Company footprint
- 15.5.5.2 Region footprint
- 15.5.5.3 Product footprint
- 15.5.5.4 Application footprint
- 15.5.5.5 End-user footprint
- 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 15.6.1 PROGRESSIVE COMPANIES
- 15.6.2 RESPONSIVE COMPANIES
- 15.6.3 DYNAMIC COMPANIES
- 15.6.4 STARTING BLOCKS
- 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
- 15.6.5.1 Detailed list of key startups/SMEs
- 15.6.5.2 Competitive benchmarking of startups/SMEs
- 15.7 COMPANY VALUATION & FINANCIAL METRICS
- 15.7.1 FINANCIAL METRICS
- 15.7.2 COMPANY VALUATION
- 15.8 BRAND/PRODUCT COMPARISON
- 15.9 COMPETITIVE SCENARIO
- 15.9.1 PRODUCT LAUNCHES & APPROVALS
- 15.9.2 DEALS
- 15.9.3 EXPANSIONS
16 COMPANY PROFILES
- 16.1 KEY PLAYERS
- 16.1.1 BIOMERIEUX
- 16.1.1.1 Business overview
- 16.1.1.2 Products offered
- 16.1.1.3 Recent developments
- 16.1.1.3.1 Product launches & approvals
- 16.1.1.3.2 Deals
- 16.1.1.3.3 Other developments
- 16.1.1.4 MnM view
- 16.1.1.4.1 Right to win
- 16.1.1.4.2 Strategic choices
- 16.1.1.4.3 Weaknesses & competitive threats
- 16.1.2 WATERS CORPORATION
- 16.1.2.1 Business overview
- 16.1.2.2 Products offered
- 16.1.2.3 Recent developments
- 16.1.2.3.1 Product approvals
- 16.1.2.3.2 Deals
- 16.1.2.4 MnM view
- 16.1.2.4.1 Right to win
- 16.1.2.4.2 Strategic choices
- 16.1.2.4.3 Weaknesses & competitive threats
- 16.1.3 DANAHER CORPORATION
- 16.1.3.1 Business overview
- 16.1.3.2 Products offered
- 16.1.3.3 Recent developments
- 16.1.3.3.1 Product approvals
- 16.1.3.3.2 Deals
- 16.1.3.4 MnM view
- 16.1.3.4.1 Right to win
- 16.1.3.4.2 Strategic choices
- 16.1.3.4.3 Weaknesses & competitive threats
- 16.1.4 ABBOTT LABORATORIES
- 16.1.4.1 Business overview
- 16.1.4.2 Products offered
- 16.1.4.3 Recent developments
- 16.1.4.3.1 Product approvals
- 16.1.4.4 MnM view
- 16.1.4.4.1 Right to win
- 16.1.4.4.2 Strategic choices
- 16.1.4.4.3 Weaknesses & competitive threats
- 16.1.5 THERMO FISHER SCIENTIFIC INC.
- 16.1.5.1 Business overview
- 16.1.5.2 Products offered
- 16.1.5.3 Recent developments
- 16.1.5.3.1 Product launches
- 16.1.5.3.2 Deals
- 16.1.5.4 MnM view
- 16.1.5.4.1 Right to win
- 16.1.5.4.2 Strategic choices
- 16.1.5.4.3 Weaknesses & competitive threats
- 16.1.6 BRUKER CORPORATION
- 16.1.6.1 Business overview
- 16.1.6.2 Products offered
- 16.1.6.3 Recent developments
- 16.1.6.3.1 Product launches & approvals
- 16.1.6.3.2 Deals
- 16.1.7 QUIDELORTHO CORPORATION
- 16.1.7.1 Business overview
- 16.1.7.2 Products offered
- 16.1.7.3 Recent developments
- 16.1.7.3.1 Product launches & approvals
- 16.1.7.3.2 Deals
- 16.1.7.3.3 Expansions
- 16.1.8 SARTORIUS AG
- 16.1.8.1 Business overview
- 16.1.8.2 Products offered
- 16.1.9 MERCK KGAA
- 16.1.9.1 Business overview
- 16.1.9.2 Products offered
- 16.1.9.3 Recent developments
- 16.1.9.3.1 Product launches & approvals
- 16.1.10 F. HOFFMANN-LA ROCHE LTD
- 16.1.10.1 Business overview
- 16.1.10.2 Products offered
- 16.1.10.3 Recent developments
- 16.1.10.3.1 Product launches & approvals
- 16.1.10.3.2 Deals
- 16.1.11 CHARLES RIVER LABORATORIES, INC.
- 16.1.11.1 Business overview
- 16.1.11.2 Products offered
- 16.1.11.3 Recent developments
- 16.1.11.3.1 Product launches
- 16.1.11.3.2 Deals
- 16.1.12 NEOGEN CORPORATION
- 16.1.12.1 Business overview
- 16.1.12.2 Products offered
- 16.1.12.3 Recent developments
- 16.1.12.3.1 Product launches
- 16.1.13 BIO-RAD LABORATORIES, INC.
- 16.1.13.1 Business overview
- 16.1.13.2 Products offered
- 16.1.13.3 Recent developments
- 16.1.13.3.1 Product launches & approvals
- 16.1.13.3.2 Deals
- 16.1.14 SHIMADZU CORPORATION
- 16.1.14.1 Business overview
- 16.1.14.2 Products offered
- 16.1.14.3 Recent developments
- 16.1.15 RAPID MICRO BIOSYSTEMS, INC.
- 16.1.15.1 Business overview
- 16.1.15.2 Products offered
- 16.1.15.3 Recent developments
- 16.2 OTHER PLAYERS
- 16.2.1 DON WHITLEY SCIENTIFIC LIMITED
- 16.2.2 GRADIENTECH
- 16.2.3 RQMICRO AG
- 16.2.4 COLIFAST AS
- 16.2.5 HYGIENA LLC
- 16.2.6 COPAN DIAGNOSTICS INC.
- 16.2.7 PERKINELMER INC.
- 16.2.8 HARDY DIAGNOSTICS
- 16.2.9 CHARM SCIENCES
- 16.2.10 R-BIOPHARM
17 RESEARCH METHODOLOGY
- 17.1 RESEARCH DATA
- 17.2 RESEARCH APPROACH
- 17.2.1 SECONDARY RESEARCH
- 17.2.1.1 Key data from secondary sources
- 17.2.2 PRIMARY DATA
- 17.2.2.1 Primary sources
- 17.2.2.2 Key data from primary sources
- 17.2.2.3 Key industry insights
- 17.3 MARKET SIZE ESTIMATION
- 17.3.1 BOTTOM-UP APPROACH
- 17.3.1.1 Approach 1: Company revenue estimation approach
- 17.3.1.2 Approach 2: Presentations of companies and primary interviews
- 17.3.1.3 Growth forecast
- 17.3.2 TOP-DOWN APPROACH
- 17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
- 17.5 MARKET SHARE ANALYSIS
- 17.6 RESEARCH ASSUMPTIONS
- 17.6.1 PARAMETRIC ASSUMPTIONS
- 17.6.2 GROWTH RATE ASSUMPTIONS
- 17.7 RESEARCH LIMITATIONS
- 17.8 RISK ASSESSMENT
18 APPENDIX
- 18.1 DISCUSSION GUIDE
- 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 18.3 CUSTOMIZATION OPTIONS
- 18.4 RELATED REPORTS
- 18.5 AUTHOR DETAILS